Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 8)*
|
Anixa Biosciences Inc (Name of Issuer) |
Common Stock (Title of Class of Securities) |
03528H109 (CUSIP Number) |
Amit Kumar c/o Anixa Biosciences, Inc., 3150 Almaden Expressway, Suite 250 San Jose, CA, 95118 408-708-9808 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/04/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 03528H109 |
| 1 |
Name of reporting person
Amit Kumar | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,173,097.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
16.3 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock |
| (b) | Name of Issuer:
Anixa Biosciences Inc |
| (c) | Address of Issuer's Principal Executive Offices:
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE,
CALIFORNIA
, 95118. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 16.3% |
| (b) | 6,173,097 shares, consisting of: (i) 569,925 shares of common stock held directly and (ii) 5,603,172 shares of common stock issuable upon exercise of stock options held directly by Reporting Person and exercisable within 60 days. |
| (c) | As of the date hereof, Dr. Kumar beneficially owns 6,173,097 shares of the Issuer, consisting of 569,925 shares of common stock held directly and 5,603,172 shares of common stock issuable upon exercise of stock options held directly and exercisable within 60 days. Such shares represent a total of 16.3% of the Issuer's outstanding shares of common stock, an increase from the 15.1% reported on Dr. Kumar's Amendment No. 7 to Schedule 13D. The change in ownership is the result of market purchases, the vesting of previously outstanding stock options and a change in the number of stock options that are not yet exercisable but will be exercisable within 60 days. The triggering event for this filing was Dr. Kumar's purchase of 10,000 shares of common stock on June 4, 2025. Dr. Kumar has the sole power to vote or direct the vote of, and to dispose or direct the disposition of, the entirety of the number of shares indicated immediately above. There are no other persons known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|